1. Home /
  2. Biotechnology

Biotechnology

Clementia Pharmaceuticals Soars After Deal to Be Bought by France's Ipsen

Clementia Pharmaceuticals Soars After Deal to Be Bought by France's Ipsen

France's Ipsen agrees to buy Clementia Pharmaceuticals in a deal worth up to $1.31 billion.

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

Roche Aims to Buy Spark for $5 Billion: Wall Street Journal

Roche Aims to Buy Spark for $5 Billion: Wall Street Journal

Predicted price would be nearly $3 billion over Spark's market cap as of Friday's close, but Roche spokesman claims report is 'market rumor.'

Voyager Shares Take Off on Parkinson's Disease Development Deal

Voyager Shares Take Off on Parkinson's Disease Development Deal

AbbVie to provide multi-million-dollar financing to Voyager to develop and commercialize potential Parkinson's treatment.

Bausch Health Swings to Loss but Revenue Tops Analysts' Expectations

Bausch Health Swings to Loss but Revenue Tops Analysts' Expectations

Bausch Health swings to a loss in the fourth quarter but issues positive revenue guidance for fiscal 2019.

3 Small Biotechs to Watch as Earnings Season Winds Down

3 Small Biotechs to Watch as Earnings Season Winds Down

One already is up nicely on its results, while the other two should issue reports of interest in the next few days.

Medtronic Reports Strong Surgical Product Sales on Way to Earnings Beat

Medtronic Reports Strong Surgical Product Sales on Way to Earnings Beat

Medtronic raises its full-year earnings forecast above analysts' estimates.

Behind the Cutting Edge Technology: The History of Amgen

Behind the Cutting Edge Technology: The History of Amgen

This biotechnology company got it's start California. Watch 'Behind the Label' TheStreet's new video series to learn more.

I Like These 2 Smaller Name Biotech Stocks

I Like These 2 Smaller Name Biotech Stocks

I still believe it will be a big year for buyouts across the biotech industry.

Moderna's Small Base Could Surprise on the Upside

Moderna's Small Base Could Surprise on the Upside

Prices have moved above the early January high giving us the simple definition of an uptrend.